Cleveland HeartLab Adds Two Additional Patents to its Extensive Intellectual Property Position

May 4, 2017

Cleveland HeartLab Inc. (CHL), the premier cardiovascular disease (CVD) management company, announced today that two new patents for Myeloperoxidase (MPO) testing have been issued:  U.S. Patent No. 9,581,597 and U.S. Patent No. 9,612,242.  Cleveland HeartLab is the exclusive license holder for MPO testing, which is covered by a number of patents including these two newly […]

Read More...

Best of Tech Awards honors 7 companies during Tech Week

April 29, 2017

Tech Company of the Year Winner: Futuri Media About 200 people came out Thursday night to find out which seven companies would claim the top Best of Tech Awards at OHTec’s 11th annual event held at Trinity Cathedral in Cleveland. From startup companies that were recognized earlier in the week, to Avon High School winning a […]

Read More...

The University of Florida College of Journalism and Communications Creates R&D Lab With Futuri Media

April 25, 2017

The University of Florida College of Journalism and Communications (UFCJC) and media technology innovator Futuri Media Monday announced a unique partnership on an unprecedented research and development lab.   Read more…

Read More...

Cleveland HeartLab Adds New Patent to its Extensive Intellectual Property Position

February 24, 2017

Cleveland HeartLab Inc. (CHL), the premier cardiovascular disease (CVD) management company, announced today that a new patent for Myeloperoxidase (MPO) testing has been issued, U.S. Patent No. 9,575,065.  Cleveland HeartLab is the exclusive license holder for MPO testing, which is covered by a number of patents including this newly issued patent.  Originally discovered and developed […]

Read More...

Futuri Media Unveils New Enhancements For POST Podcast Publishing System

February 9, 2017

FUTURI MEDIA‘s POST podcast publishing system has received some new enhancements, including a touchscreen interface, editing tool, and planning module. Read more: 

Read More...

Cleveland startup GenomOncology adds vice president of medical affairs

December 1, 2016

GenomOncology, a Cleveland company that has developed a technology platform to streamline the use of next-generation sequencing data in medical care and research, said it has named Dr. Joshua F. Coleman as vice president of medical affairs. Read More…

Read More...

USL, Groupmatics Announce Collaborative Partnership

November 9, 2016

CLEVELAND, Ohio – The United Soccer League and Groupmatics, an online group sales platform, have announced a collaborative partnership that will allow the USL’s clubs to utilize the third-party technology to increase revenue opportunities and streamline much of the group sales process between team’s sales executives and their group clients. Read More…

Read More...

PointClickCare Expands Partnership with COMS Interactive

October 19, 2016

Value-based healthcare is creating demand for clinical transparency and quality outcomes reporting that directly impacts a senior care organization’s bottom line. Today, PointClickCare, the leading cloud-based software platform for the senior care continuum, and COMS Interactive, the clinical care and quality improvement leader in the senior care market, are collaborating to answer this demand.   […]

Read More...

Futuri Media Ranks on Inc. Magazine’s List of Fastest-Growing Private Companies for Third Consecutive Year

October 10, 2016

For the third year in a row, Futuri Media, the foremost innovator in technology for broadcast media, has been named to the Inc. 5000 list as one of the fastest-growing private companies in America. The company ranked among the upper half of the list for the third straight year with a 156% three-year growth rate. […]

Read More...

GenomOncology Enhances The GO Clinical Workbench For Hematological Cancer Analysis And Reporting

October 10, 2016

GenomOncology today announced the recent extension of the GO Clinical Workbench to support Hematologic cancer testing and decision support. Molecular diagnostic laboratories across the country have used GenomOncology’s workbench for their solid tumor testing needs for over two years. GenomOncology’s clients have recently begun to validate and launch Hematologic malignancy focused panels. With new guidelines […]

Read More...